Follow Me on Pinterest

Friday, August 6, 2021

Foreign company pursuit of cell therapy commercialization in Japan: strategies and considerations

 I'm thrilled to announce that I will be presenting at the upcoming 5th Annual Cell & Gene Therapy World Asia, live streaming on 15th and 16th September 2021.

I will be presenting on "Foreign company pursuit of cell therapy commercialization in Japan: strategies and considerations" at 9:30AM (Singapore Time) on 16th September.

My presentation will cover the following topics:

·       Unique constraints and opportunity for regenerative medicine in Japan

·       Practical strategies for building a virtual team to support real progress

·       PMDA conditional approval -- not the only expedited commercialization pathway in Japan

In preparing for this presentation, I had opportunity to speak with Gladys Koh of IMAPAC to discuss

1.    key trends shaping the cell therapy industry moving forward in a post-pandemic world in Asia
2.    exciting technologies or developments that have caught my attention in the past year
3.    thoughts on how regulations pertaining to cell therapies can be evolved to allow the progress of the industry
4.    current struggles with respect to commercialization of cell therapies and how would they might be overcome
5.    key challenges this industry faces and is currently trying to overcome
6.    developments should the industry look out for from RepliCel Life Sciences Inc. in the coming year
8.    some of the key takeaways the audience can expect from my presentation

To view the interview, https://youtu.be/p2oZPbgFkMQ


Click here and here for a written advance peak at a few thoughts from some of the following speakers involved in the event such as:

Gregory Fiore, President & CEO, Exacis Biotherapeutics, USA

Zhimei Du, Global Head Process Cell Sciences, Cell/Gene Therapy, Merck & Co, USA

William Hung, Assistant General Manager, MariaVon, Taiwan

Hardy TS Kagimoto, Chairman & CEO, Healios, Japan

Pascal Touchon, President & CEO, Atara Biotherapeutics, USA 

Joy (Shuxia) Zhou, Head of Drug Product Development, Cell Therapy, Takeda, USA

Magali Taiel, Chief Medical Officer, GenSight Biologics, France

Andreas Weiler, Global Head of External Supply Cell & Gene Therapy, Novartis,  Switzerland

Seong-Wook Lee, President & CEO, Rznomics Inc., Korea

Yu Zhang, SVP & Chief Scientific Officer, VCANBIO Cell & Gene Engineering, China

Shi-Jiang (John) Lu, President and CEO, HebeCell Corporation

Devyn Smith, CEO, Arbor Biotechnologies, USA

Lee Buckler, President & CEO, RepliCel Life Sciences Inc.



Thursday, July 15, 2021

Cell and gene data innovation and multi-stakeholder data transfer

Hello readers. It's been awhile. I'm pleased to be working with Reuters on some events including this upcoming webinar on how to utilize RWD in cell and gene therapies with speakers from Novartis, BMS and Salesforce. Click here for more info.

The requirements of complex and delicate value chains within cell and gene therapies (CGT) is something pharma has traditionally never seen before. Leaders in CGT are innovating data sharing approaches by utilizing RWE and RWD across the value chain, and achieving multi-stakeholder alignment, to ensure commercial success.












Join C&GT delivery trailblazers BMS, Novartis and Salesforce to learn how to turn data in to true insights: that enhance the science, reduce the cost of deliver, improve commercial decision-making and elevate the patient experience.

Sign up for the webinar “Cell and gene data innovation and multi-stakeholder data transfer” here.

When you join, you will learn how to:

                 Reimagine the technology: digitally transform existing data integration models for cell and gene therapies

                 Reach for the future together: develop a multi-stakeholder strategy collaboratively, that aligns on needs and capabilities

                 Cross-capture and utilize data flow from R&D through to launch to win the marketplace with science and data

                 Prepare for and address the major barriers to success: such as infrastructure non-readiness, digitally siloed stakeholders, underdeveloped partnerships, and data illiteracy

                 Turn data in to true insights: that enhance the science, reduce the cost of deliver, improve commercial decision making and elevate the patient experience

Tune in live to the free webinar on July 29 at 11am ET/4pm BST, or sign up to receive the recording here.

Please also feel free to share with your colleagues working in C&G therapy, so they can benefit too. 

Lee